Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
585.00    -13.00 (-2.17%)
Bid:
584.00
Ask:
586.00
Spread: 2.00 (0.342%)
Market Cap: £509.68m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Interim Management Statement

21 Jul 2015 07:00

RNS Number : 5569T
Victrex PLC
21 July 2015
 



 

 

 

 

 

 

21 July 2015

 

Victrex plc - Interim Management Statement

 

"Solid trading and acquisition of Kleiss Gears"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today announces its Interim Management Statement for the period 1 April 2015 to 30 June 2015 (Q3) and the acquisition of Kleiss Gears Incorporated for a cash consideration of approximately $6m.

 

Victrex saw solid trading against tougher comparatives during Q3, with our performance reflecting continuing growth across our industrial markets, which is offsetting sales to Oil & Gas and a lower contribution from our Invibio medical business. Third quarter Group revenue of £64.5m was flat compared to the prior year period (Q3 2014: £64.2m) and slightly ahead in constant currency, with third quarter Group sales volume of 1,070 tonnes 17% ahead of the prior year (Q3 2014: 911 tonnes). Year to date Group sales volume of 3,098 tonnes is 24% ahead of the prior year (YTD 2014: 2,495 tonnes).

 

Within Victrex Polymer Solutions (VPS), Consumer Electronics volumes remain strong and, as previously communicated, we expect volumes from the current opportunity to continue through our 2016 financial year.

 

In our Invibio medical business, the sales improvement trend we saw in Q2 did not continue as we anticipated during Q3. Overall sales were down during the quarter, driven lower by the continued effects of consolidation in the US medical device industry. However, outside of the US, sales in Europe and emerging markets remain positive. On a full year basis, we now anticipate Invibio revenue will be lower than 2014. Our expectation is for full year sales to decline by a broadly similar level to the 4% reduction seen in the first half year.

 

All of our new product platforms and adoption programmes continue to make positive progress, including those in medical for PEEK-OPTIMA® HA-Enhanced (Spine), Dental, Trauma and Knee.

 

Acquisition of Kleiss Gears

Victrex is pleased to announce the acquisition of Kleiss Gears, a US based polymer gears' manufacturer, for approximately $6m (£3.8m) in cash.

 

Kleiss has over 20 years' experience of unique design and precision moulding capability in gears, and will benefit from Victrex's materials know-how, existing customer relationships and global commercial reach. Kleiss has early stage commercialisation of PEEK gear programmes, alongside the rest of its mainly industrial focused gears business.

 

The acquisition is in line with Victrex's strategy of moving further downstream and investing in growth acceleration opportunities for its pipeline projects. It offers the opportunity to accelerate Victrex's PEEK gear proposition to the automotive industry, in line with our aim to double the amount of PEEK volume in cars over the medium term.

 

For its 2014 financial year, Kleiss had revenues of approximately $4m and employed 26 people.

 

Outlook

For the year as a whole, whilst challenges continue in the Oil & Gas market and in improving Invibio's performance, our overall momentum remains positive and we still expect to fully overcome the impact of foreign currency. Consequently, and reflecting our balanced portfolio, Victrex remains well positioned to deliver profit progress over the full year.

 

Cash generation remains healthy and there have been no significant changes to the Group's financial position since our interim results announcement.

 

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver leading edge solutions to our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

 

Investor and analyst call:

A call for investors and analysts will be held today, Tuesday 21 July at 08.00am UK time. For dial in details please contact Laura Stewart at Pendomer Communications: laura.stewart@pendomer.com or +44 (0) 203 603 5229.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEASXEAEDSEFF
Date   Source Headline
30th Nov 20189:39 amRNSTotal Voting Rights
28th Nov 20189:59 amRNSDirector Declaration
19th Nov 201812:14 pmRNSDirector/PDMR Shareholding
14th Nov 201810:01 amRNSDirector Declaration
31st Oct 201810:29 amRNSTotal Voting Rights
17th Oct 201811:23 amRNSDirector/PDMR Shareholding
28th Sep 20189:17 amRNSTotal Voting Rights
18th Sep 201812:06 pmRNSDirector/PDMR Shareholding
31st Aug 201810:52 amRNSTotal Voting Rights
22nd Aug 201812:46 pmRNSHolding(s) in Company
17th Aug 201811:31 amRNSDirector/PDMR Shareholding
31st Jul 201810:56 amRNSTotal Voting Rights
27th Jul 20184:01 pmRNSHolding(s) in Company
25th Jul 201811:16 amRNSDirector/PDMR Shareholding
25th Jul 20187:00 amRNSInterim Management Statement
17th Jul 201812:47 pmRNSDirector/PDMR Shareholding
29th Jun 20189:26 amRNSTotal Voting Rights
19th Jun 20183:25 pmRNSDirector/PDMR Shareholding
1st Jun 20189:04 amRNSBlock listing Interim Review
31st May 20181:29 pmRNSTotal Voting Rights
17th May 20182:37 pmRNSDirector/PDMR Shareholding
16th May 20183:47 pmRNSDirector/PDMR Shareholding
14th May 20187:01 amRNSDirectorate Change
14th May 20187:00 amRNSHalf-year Report
1st May 201811:42 amRNSTotal Voting Rights
30th Apr 201811:40 amRNSAdditional Listing
17th Apr 20184:28 pmRNSDirector/PDMR Shareholding
28th Mar 201810:00 amRNSGroup Financial Director Update
19th Mar 20183:13 pmRNSDirector/PDMR Shareholding
1st Mar 20182:22 pmRNSTotal Voting Rights
19th Feb 20184:30 pmRNSDirector/PDMR Shareholding
12th Feb 201810:32 amRNSDirectorate Change
12th Feb 201810:30 amRNSDirectorate Change
9th Feb 201811:50 amRNSResult of AGM
9th Feb 201811:24 amRNSDirector/PDMR Shareholding
9th Feb 20187:00 amRNSAGM & Q1 IMS
7th Feb 20184:16 pmRNSHolding(s) in Company
6th Feb 20181:44 pmRNSDirectorate Change
1st Feb 201812:13 pmRNSTotal Voting Rights
25th Jan 20189:49 amRNSHolding(s) in Company
17th Jan 20184:25 pmRNSDirector/PDMR Shareholding
4th Jan 201812:06 pmRNSNomination for election of Non-executive Directors
4th Jan 201812:00 pmRNSAnnual Financial Report
29th Dec 201710:00 amRNSTotal Voting Rights
19th Dec 20174:24 pmRNSDirector/PDMR Shareholding
18th Dec 201710:08 amRNSDirector/PDMR Shareholding
8th Dec 20171:19 pmRNSDirector/PDMR Shareholding
5th Dec 201711:39 amRNSDirector/PDMR Shareholding
5th Dec 20177:01 amRNSDirectorate Change
5th Dec 20177:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.